Vitamin D Supplementation in Children with Alopecia Areata

Letters to Editor
Sir, Alopecia areata (AA) is a common worldwide disease, with a frequency ranging from 0.1% to 0.2%. Pediatric AA constitutes approximately 20% of all cases. AA is characterized by hair loss in regions, complete baldness, or complete body. AA is considered an autoimmune disease. However, other etiopathogenic factors have been considered as causes of AA. The course of AA is unpredictable. Response to treatment is variable; none therapeutic agent is curative or preventive. [1] Vitamin D is a modulator of both the innate and adaptive immune system. Vitamin D deficiency has been reported in a variety of autoimmune diseases including AA. Keratinocytes express Vitamin D receptors (VDRs). Expression of VDRs in keratinocytes is necessary for the normal hair cycle. Lack of VDRs reduces hair follicle growth. It has been hypothesized that Vitamin D deficiency might be a trigger for the induction of autoimmunity playing a role in AA. [2] [3] [4] [5] To the best of our knowledge, there are no studies to evaluate the use of Vitamin D in AA treatment.
We conducted a retrospective chart review of 12 patients with clinical diagnosis of chronic/relapsing AA and Vitamin D insufficiency (<30 ng/ml) or Vitamin D deficiency (<20 ng/ml) between January 2015 and November 2016. Demographic, clinical, and laboratory data of the patients were recorded. Two patients were excluded on the basis that lack of follow-up. Scalp assessments were performed using severity of alopecia tool (SALT score). Serum 25-hydroxy-vitamin D (25-[OH]-vitamin D) levels were measured at least twice using a commercial enzyme immunoassay. We defined Vitamin D insufficiency as Vitamin D <30 ng/ml and Vitamin D deficiency as <20 ng/ml. Children under 10 years received 400 IU/800 IU (insufficiency/deficiency) of Vitamin D per day; children up 10 years received 800 IU/1600 IU (insufficiency/deficiency) of Vitamin D per day. Table 1 summarizes the patient characteristics and Table 2 summarizes the clinical outcomes. After median treatment duration of 10 (range 6-14) months and a median of 4 (range 2-7) follow-up visits, we found no significant response to the Vitamin D supplementation in the treatment of AA, either regrowth or activity of hair loss. Table 3 shows initial and latest SALT for each patient. Decreased level of 25-(OH)-vitamin D was not correlated with pattern or extent of hair loss. The least values were present in patchy AA. The serum level of 25-(OH)-vitamin D was lower in patients with nail involvement when compared with patients without nail affliction. In the current study, there was a lack of association between 25-(OH)-vitamin D levels and family history of autoimmune diseases, personal history of autoimmune diseases, and duration of AA and of its remitting-relapsing course. Topical treatments were continued and/or adjusted as needed during the Vitamin D supplementation in all our patients.
We present a group of ten patients with chronic/relapsing AA and reduced levels of 25-[OH]-vitamin D. The use of Vitamin D in disease treatment has not a significant hair regrowth. The retrospective nature of the data, small sample size, and lack of a control group are limitations. We confirm decreased serum 25-(OH)-vitamin D levels in patients with AA, which may indicate a role of Vitamin D deficiency in the pathogenesis of the disease. Future studies are needed to provide evidence about the causal risk factor of Vitamin D deficiency for AA occurrence and clinical trial to evaluate the use of Vitamin D as a reasonable treatment strategy.
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